AU2003304117B2 - Extracting and purifying enzymes - Google Patents
Extracting and purifying enzymes Download PDFInfo
- Publication number
- AU2003304117B2 AU2003304117B2 AU2003304117A AU2003304117A AU2003304117B2 AU 2003304117 B2 AU2003304117 B2 AU 2003304117B2 AU 2003304117 A AU2003304117 A AU 2003304117A AU 2003304117 A AU2003304117 A AU 2003304117A AU 2003304117 B2 AU2003304117 B2 AU 2003304117B2
- Authority
- AU
- Australia
- Prior art keywords
- extract
- pde
- process according
- magnesium
- calcium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 102000004190 Enzymes Human genes 0.000 title description 13
- 108090000790 Enzymes Proteins 0.000 title description 13
- 239000000284 extract Substances 0.000 claims description 86
- 101100243082 Caenorhabditis elegans pde-1 gene Proteins 0.000 claims description 67
- 230000000694 effects Effects 0.000 claims description 49
- 238000000034 method Methods 0.000 claims description 46
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 31
- 239000011777 magnesium Substances 0.000 claims description 31
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 30
- 239000011575 calcium Substances 0.000 claims description 30
- 229910052791 calcium Inorganic materials 0.000 claims description 29
- 229910052749 magnesium Inorganic materials 0.000 claims description 29
- 235000007340 Hordeum vulgare Nutrition 0.000 claims description 24
- 238000010438 heat treatment Methods 0.000 claims description 17
- 108091028664 Ribonucleotide Proteins 0.000 claims description 12
- 239000002336 ribonucleotide Substances 0.000 claims description 12
- 125000002652 ribonucleotide group Chemical group 0.000 claims description 12
- 101001117086 Dictyostelium discoideum cAMP/cGMP-dependent 3',5'-cAMP/cGMP phosphodiesterase A Proteins 0.000 claims description 10
- 238000005571 anion exchange chromatography Methods 0.000 claims description 8
- 150000001768 cations Chemical class 0.000 claims description 8
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 claims description 6
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 claims description 6
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 claims description 4
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 claims description 4
- 108091033319 polynucleotide Proteins 0.000 claims description 4
- 102000040430 polynucleotide Human genes 0.000 claims description 4
- 230000001737 promoting effect Effects 0.000 claims description 3
- 238000004587 chromatography analysis Methods 0.000 claims description 2
- 240000005979 Hordeum vulgare Species 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 29
- 241000209219 Hordeum Species 0.000 description 23
- 239000000243 solution Substances 0.000 description 19
- 238000000746 purification Methods 0.000 description 15
- 239000000872 buffer Substances 0.000 description 8
- 239000000287 crude extract Substances 0.000 description 8
- 239000007983 Tris buffer Substances 0.000 description 7
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 7
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 6
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 6
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000005349 anion exchange Methods 0.000 description 4
- 229910001424 calcium ion Inorganic materials 0.000 description 4
- 238000004925 denaturation Methods 0.000 description 4
- 230000036425 denaturation Effects 0.000 description 4
- 238000011033 desalting Methods 0.000 description 4
- 229910001425 magnesium ion Inorganic materials 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000012901 Milli-Q water Substances 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- RQFCJASXJCIDSX-UHFFFAOYSA-N 14C-Guanosin-5'-monophosphat Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(COP(O)(O)=O)C(O)C1O RQFCJASXJCIDSX-UHFFFAOYSA-N 0.000 description 2
- 108010051457 Acid Phosphatase Proteins 0.000 description 2
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- RQFCJASXJCIDSX-UUOKFMHZSA-N guanosine 5'-monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O RQFCJASXJCIDSX-UUOKFMHZSA-N 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- RWOAVOYBVRQNIZ-BFHYXJOUSA-N p-nitrophenyl thymidine 5'-monophosphate Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OC=2C=CC(=CC=2)[N+]([O-])=O)[C@@H](O)C1 RWOAVOYBVRQNIZ-BFHYXJOUSA-N 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- 102000013563 Acid Phosphatase Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101100296726 Caenorhabditis elegans pde-5 gene Proteins 0.000 description 1
- 239000005980 Gibberellic acid Substances 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 102100021969 Nucleotide pyrophosphatase Human genes 0.000 description 1
- 108010010677 Phosphodiesterase I Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102100035703 Prostatic acid phosphatase Human genes 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007872 degassing Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000011143 downstream manufacturing Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000019264 food flavour enhancer Nutrition 0.000 description 1
- IXORZMNAPKEEDV-UHFFFAOYSA-N gibberellic acid GA3 Natural products OC(=O)C1C2(C3)CC(=C)C3(O)CCC2C2(C=CC3O)C1C3(C)C(=O)O2 IXORZMNAPKEEDV-UHFFFAOYSA-N 0.000 description 1
- IXORZMNAPKEEDV-OBDJNFEBSA-N gibberellin A3 Chemical compound C([C@@]1(O)C(=C)C[C@@]2(C1)[C@H]1C(O)=O)C[C@H]2[C@]2(C=C[C@@H]3O)[C@H]1[C@]3(C)C(=O)O2 IXORZMNAPKEEDV-OBDJNFEBSA-N 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000004890 malting Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- -1 p-nitrophenyl ester Chemical class 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 108020004418 ribosomal RNA Proteins 0.000 description 1
- 238000009938 salting Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Landscapes
- Enzymes And Modification Thereof (AREA)
Description
WO 2004/101613 PCT/AU2003/001618 1 Extracting and purifying enzymes Field of the invention The invention relates to extracting and purifying an enzyme from a cell, particularly, but not exclusively, to extracting and purifying a 5' phosphodiesterase from 5 a barley cell. Background of the invention Phosphodiesterase 1 (orthophosphoric diester phosphohydrolase, EC 3.1.4.1; herein "PDE-1") is an enzyme that catalyses the hydrolysis of a phosphodiester bond at the 3' hydroxyl end of ribopolynucleotide to yield a 5' ribonucleotide. 10 PDE-1 is particularly important to food and pharmaceutical industries because the 5' ribonucleotides produced by PDE-1 -mediated cleavage of yeast RNA are useful as flavour enhancers. Barley cells or rootlets are used in the food industry as a source of PDE-1. The processes for purification of PDE-1 from barley rootlets tend to be difficult to 15 operate on a commercial scale, in terms of requiring sophisticated extraction and separation techniques, multiple steps and expensive reagents and equipment. Some processes are characterised by an unacceptable loss or wastage of PDE-1. Other processes tend to produce a final product that has a sub-optimal specific activity. In view of the above, there is a need for improved processes for purification of 20 PDE-1. Summary of the invention The invention seeks to at least minimise one or more of the above identified problems or limitations and/or to provide an improved process for purification of PDE- 1. In one aspect, the invention provides a process for purifying PDE-1 from a cell. 25 The process includes the step of heating an extract of a cell formed from a solution including at least one divalent cation, to increase the specific activity of PDE-1 in the extract.
WO 2004/101613 PCT/AU2003/001618 2 In another aspect, the invention provides a process for purifying PDE-l from a barley cell. The process includes the following steps; (a) releasing PDE-1 from the cell into a solution including calcium and magnesium to form an extract; and 5 (b) heating the extract to increase the specific activity of PDE-1 in the extract. In another aspect, the invention provides a process for purifying PDE-1 from a barley cell. The process includes the following steps: (a) releasing PDE-1 from the cell into a solution including calcium and magnesium to form an extract; 10 (b) heating the extract to increase the specific activity of PDE-1 in the extract; and (c) utilising anion exchange chromatography to purify PDE-1 from the heated extract. Typically the cell is a barley cell, such as a cell derived from a barley rootlet. 15 In another aspect, the invention provides PDE-1 produced by the process of the invention. In another aspect, the invention provides a cell including PDE-l produced by the process of the invention. In another aspect, the invention provides a process for producing a ribonucleotide. 20 The process includes the step of contacting a polyribonucleotide with PDE-1 produced by the process of the invention, to produce the 5' ribonucleotide. In another aspect, the invention provides a ribonucleotide produced by the above described process. Detailed description of the embodiments 25 As described herein, the inventor has found that heat treatment of an extract of a barley cell or rootlet in a solution comprising at least one divalent cation permits the specific activity of the extract to be increased. For example, the specific activity of a heat treated extract of a barley rootlet formed from a solution comprising calcium and WO 2004/101613 PCT/AU2003/001618 3 magnesium was observed to increase 2.6 fold over a non heat treated sample (312.6 x10 3 compared with 122 x 10-3 pmoles/min/mL). Further, a heat treated extract containing calcium and magnesium was observed to have an improved specific activity (78 x 10 tmoles/min/mL) compared with a heat treated extract containing no calcium and 5 magnesium (46 x 10- 3 pimoles/min/mL). This is a significant finding because it permits heat treatment, a purification step that is relatively simple to operate on a commercial scale, to be implemented with minimal loss of activity of PDE-1. It is believed that the specific activity of the extract is increased because the 10 divalent cation protects PDE-1 from denaturation at temperatures at which other proteins in the extract, including phosphomonoesterase, are degraded. Typically, the at least one divalent cation in the solution may be magnesium and/or calcium. For example, the solution may contain MgCl 2 and/or CaC1 2 . The magnesium and calcium ions may be included in the extract in an amount to 15 permit control of the denaturation of PDE-1 when the extract is heated. Typically, magnesium and calcium are included in the extract in an amount to at least limit the denaturation of PDE-1 when the extract is heated. For example, the concentration of calcium may be less than 100 mM and the concentration of magnesium may be less than 100 mM. 20 A concentration of calcium and magnesium in a range between about 10 to 50 mM is particularly useful as further down stream processing of the extract for further purification, such as anion exchange chromatography, may require removal of calcium and magnesium. Accordingly a concentration of calcium ions of about 50 mM and a concentration of magnesium ions of about 50 mM is particularly useful. 25 It is believed that phosphomonoesterase is a major constituent of an extract of a barley rootlet. Thus, the extract is typically heated to a temperature that permits denaturation of phosphomonoesterase, or otherwise, destruction of phosphomonoesterase activity in the extract. As described herein, temperatures less than 80C are suitable for this purpose.
WO 2004/101613 PCT/AU2003/001618 4 It is particularly advantageous to heat the extract to between about 45 and 75'C because at temperatures approaching 70'C and above, PDE-1 activity may be lost. Accordingly, a temperature of about 60 0 C is particularly useful. The inventor has also found that the purification of PDE-1 from a barley cell 5 extract can be improved by extracting a barley cell homogenate at 4'C in a solution including magnesium and calcium. Specifically, as described herein, the specific activity of an extract comprising calcium and magnesium after maintenance at 4'C was found to be 92 x 10 3 pmoles/min/imL as compared with the activity of an extract maintained at 4 0 C in the absence of calcium and magnesium (75 x 103 pmoles/min/mL) . 10 It is believed that maintenance of such an extract at 4'C is important because it permits PDE-1 to disassociate from solids in the extract, and accordingly, to solubilise into the liquid phase of the extract, prior to further processing of the extract, such as a heat treatment step or a chromatographic separation step. The calcium and magnesium are believed to be important for limiting hydrolysis of the enzyme during the maintenance 15 of the extract at 4'C. Thus in accordance with the invention, a process for purifying PDE-l from a barley cell includes the following steps: (a) releasing PDE-1 from the cell into a solution including calcium and magnesium to form an extract; and 20 (b) heating the extract to increase the specific activity of PDE-l in the extract. Typically, the extract is maintained in conditions for promoting solubilisation of the phosphodiesterase in the extract prior to heating the extract. The extract may be maintained at less than 10'C for less than 5 days. For example, the extract may be maintained between 0 to about 4'C for between about 1 to 25 48 hours. It is particularly advantageous to maintain the extract for 24 hours at 4'C as this improves the speed of purification protocols that comprise further purification steps. The inventor has further found PDE-l can be purified to virtual homogeneity from a barley cell extract by a process including the following steps: WO 2004/101613 PCT/AU2003/001618 5 (a) releasing PDE-1 from the cell into a solution including calcium and magnesium to form an extract; (b) heating the extract to increase the specific activity of PDE-1 in the extract; and 5 (c) utilising chromatography to purify PDE-1 from the heated extract. As described herein, PDE-l can be further purified from a heat treated barley cell extract by anion exchange chromatography. Accordingly, typically, in step (c), anion exchange chromatography is utilised to purify PDE-1 from the heated extract. The inventor has found that calcium and magnesium ions tend to limit binding of 10 PDE-1 during anion exchange chromatography. Accordingly, typically the extract is desalted before anion exchange chromatography. One way of desalting to remove magnesium and calcium ions is by ultrafiltration. Alternatively, a preparative de-salting column, such as a Hi trap 26/10 desalting column can be used. It is particularly advantageous to remove substantially all of the calcium and magnesium from the extract 15 prior to anion exchange chromatography for the purpose of maximising the yield of PDE 1 purified from the anion exchange column. Typically, the extract is maintained in conditions for promoting solubilisation of the phosphodiesterase in the extract prior to heating the extract. In the processes of the invention described above, the extract of the barley cell is 20 typically produced by homogenising barley rootlets in an appropriate buffer. One way of homogenizing rootlets is by use of a blender, such as a Waring blender. Alternatively, the extract may be produced by milling barley rootlets in an appropriate buffer. The solution into which the PDE-1 from the cell is released to form an extract is typically a buffer for controlling pH. Solutions prepared from Trisma base are examples 25 of such a solution. A solution having a concentration of no more than about 100mM Tris is suitable, however a solution having a concentration between about 20 to 50 mM Tris, for example, 25 mM Tris is particularly advantageous because as described herein, this concentration of Tris is compatible with, and permits separation of PDE-1 on, an anion exchange column.
WO 2004/101613 PCT/AU2003/001618 6 It will be understood that the processes of the invention are useful for purifying PDE-1 from cells other than barley cells. Further, it will be understood that processes of the invention are useful for isolating barley PDE-1 from cells that contain a recombinant nucleic acid molecule that encodes barley PDE-l. Examples of such cells include 5 bacterial cells and yeast cells. In another aspect, the invention provides a process for producing a ribonucleotide. The process includes the step of contacting a polyribonucleotide with PDE-1 produced by the process of the invention, to produce the ribonucleotide. Preferably the polyribonucleotide is derived from yeast RNA, such as yeast ribosomal RNA. 10 Example 1: Materials and equipment. Germinating barley seeds (Schooner variety) were obtained from Barrett Burston Malting, (Thornleigh, NSW, Australia). Thymidine 5' monophosphate p-nitrophenyl ester, Trisma base, MgCl 2 , CaCl 2 , p-nitrophenyl-phosphate, Baker's yeast RNA, bovine serum albumin, guanosine 5'-monophosphate, potassium dihydrogen orthophosphate 15 were all supplied by Sigma Aldrich (Castle Hill, NSW Australia). Yeast rRNA was prepared as a 3mg/mL standard solution in RNAse free. Milli Q water (pH7.0) in a clean room environment and inunediately frozen to minus 80'C and stored until required. Guanosine 5'-monophosphate was prepared as a 1% (w/v) stock by dissolving in 20 Milli Q water and storing at -20'C. Working solutions were prepared by diluting the stock solution to 0.01% (w/v). The buffer used for FPLC was 25mM Tris HCl (pH 8.9). The fluent buffer included 1 M NaCl. For the HPLC analysis, solvent (A) was 0.02M potassium dihydrogen 25 orthophosphate (pH 6.5) solution while solvent (B) was a 40% methanol (HPLC grade) and 60% Milli Q water mixture (pH 6.5). All solvents and buffers were degassed and filtered prior to use by passing each solution through a Millipore membrane filter, pore size 0.45 pm under vacuum for 5 minutes.
WO 2004/101613 PCT/AU2003/001618 7 An Amersham Pharmacia AKAT gradient processing FPLC system complete with a 900 model monitor, lamp and detector (set at 280nm), 920 model pump and Frac 950 fraction collector interfaced to a Compaq Deskpro Pentium III computer supporting Unicorn analytical software was used for all protein purification. The columns used 5 included a Hi Trap 26/10 desalting column connected to a Super loop 50 (to facilitate larger injection volumes), a 16/10 Hi-Load Q anion exchange column with a final purification undertaken on a Mono Q HR 5/5 column. The HPLC system used for the analysis of 5' nucleotides was a Shimadzu Liquid Chromatography unit, consisting of a Shimadzu pump (model LC-1OAi) with an on-line 10 degassing unit, SCL-1OA system controller, SPD-M1OA diode array detector and a column oven (set at 30'C), the system was controlled by a Dell Pentium III computer operating a Shimadzu class VP (version 5.03) analytical software program, The column used for the analysis of 5' ribonucleotides was an Activon Goldpak HPLC column (250mm x 4.6mm, 5mm particle size and 1 Onm pore size). Peak heights were determined 15 from chromatograms recorded at both 245 nm and 280 nm. A Pharmacia LKB UV-Visible spectrophotometer was also used to measure enzyme activity and was set at 410 nm with an aligned temperature control cell all controlled by a HP Pentium II computer operating a Biochrome 4060 enzyme kinetics software program. 20 Example 2: Preparation of a standard curve for p-nitrophenol to determine PDE-1 activity. A solution of 10 mg/100 mL of p-nitrophenol was prepared in 50mM Tris HC1 (pH 8.9) to yield a concentration of 0.719 ptmoles/ml of p-nitrophenol. Dilutions were prepared in 50mM Tris HCl (pH8.9) and read as a 4.1 mL sample size at 410 nm to 25 directly correlate with the enzyme activity absorbances at each purification step. Example 3: Preparation of a standard curve for protein to determine PDE-1 specific activity. Protein was determined using the BioRad micro assay procedure derived from the original method of Bradford utilising a standard curve produced for bovine serum WO 2004/101613 PCT/AU2003/001618 8 albumin. Each analysis was conducted in duplicate requiring incubation at room temperature for 10 minutes with the absorbance measured at 595 nm. Standards were prepared in the range of 0.2 to 1.4 mg/mL of protein. Example 4: Enzyme kinetics assay. 5 The assay solution consisted of 0.1 mL of purified PDE-1, 2.0 mL of 50mM Tris HCl (pH 8.9), lmL of lmM thymidine 5' monophosphate p-nitrophenyl ester in 50mM Tris HCl (pH 8.9) and lmL of a 50mM MgC1 2 in 50mM Tris HC1 (pH 8.9). The reaction mixture was incubated at 37'C for 30 minutes with the optical density of enzymatically produced p-nitrophenol measured at 410nm each minute to determine the PDE-1 reaction 10 kinetics. The activity was determined by extrapolation against a standard curve with 1 unit of activity defined as the micromoles ofp-nitrophenol produced from p-nitrophenyl ester per minute per mL of purified PDE-1. Specific activity was defined as the activity per milligram of purified PDE-1. 15 Example 5: Confirmation of PDE-1 activity Confirmation of enzyme activity was undertaken by reaction of the purified enzyme with 3mg/mL Baker's yeast RNA and measuring the 5'ribonucleotide products by reverse phase HPLC. The HPLC column was equilibrated with 100% buffer A for 30 minutes at a flow 20 rate of 1 ml.min ensuring the pressure remained below 180 Kpa. The ratio of solvent B in the elution system was increased linearly over 18 minutes to 40% then increased to 100% over the next 2 minutes and held for a further 2 minutes to flush any remaining strongly bound compounds. The system was automatically returned to its starting conditions over the following 8 minutes and stabilised on buffer A for a further 30 minutes before the 25 next injection. The total analysis time was 60 minutes with elution performed at 30C oven temperature. Example 6: Preparation of crude PDE-1 extract. lOg of fresh barley rootlets were obtained from seeds that had been germinating for 5 days including a 2 day steep in 5mg/kg gibberellic acid to facilitate enzyme WO 2004/101613 PCT/AU2003/001618 9 extraction. The rootlets were dispersed in l0OmL 25 mM Tris-HCl (pH7.5) containing 50mM MgCl 2 and 50mM CaCl 2 . This mixture was homogenised in a Waring blender at high speed for 1 minute and maintained at 4C for 24 hours to facilitate solubilisation of PDE-1. 5 The insoluble material was removed from the extract by filtering through double cheese cloth. The filtrate was then centrifuged at 15,000 rpm for 30 minutes at 4 0 C to remove solids and the supernatant was passed through a 0.45pLM filter and stored at 4 0 C in a sterile container with 0.01% sodium azide. This process formed the crude PDE-1 extract. 10 The activity and specific activity of the crude PDE-l extract was then determined according to Examples 2 to 4 above. Example 7: Purification of PDE-1 from the crude PDE-1 extract. The first stage of the purification process involved the removal of heat labile enzymes (primarily Acid Phosphatase [Phosphomonoesterase (PME)] EC 3.1.3.2) and 15 inhibitory proteins from the crude PDE-1 extract with the aim of reducing any loss of activity or damage to the structure of PDE-1. To inactivate PME, the crude extract was heated in a water bath to 60'C and maintained at that temperature for 1 hour. The extract was then cooled to room temperature and the pH adjusted to 8.9. The extract was then filtered through a 0.45pm filter. 20 The activity and specific activity of the heat treated PDE-1 extract was then determined according to Examples 2 to 4 above. Ion exchange chromatography was then undertaken. A 100mL sample of the extract was injected into a Super loop 50 column and desalted by FPLC on a Hi trap 26/10 desalting column at a flow rate of 7.0 mL per minute, to remove magnesium and 25 calcium. The desalted fractions were then pooled and reloaded onto the Super loop column and passed through a Hi load 16/10 anion exchange column at 3.0 mL per minute to initially fractionate PDE-1. The isolated fraction was again desalted to remove the 1 M NaCl elution buffer and was then purified by passing the fraction through the Mono Q WO 2004/101613 PCT/AU2003/001618 10 HR 5/5 column at 1.5 mL per minute. A single peak was obtained and analysed for activity and specific activity according to Examples 2 to 4 above. Example 8: Purification profile for PDE-1. The results for the purification of PDE- 1 are shown in Table 1. 5 Table I Sample Activity Specific activity Purification factor Crude extract 169 122 1 Heat treatment 156.3 312.6 2.6 Anion 267.5 1407.9 11.5 exchange Activity: x 10-3 pmoles/min/mL Specific activity: x 10-3 pmoles/min/mL/mg Example 9: Effect of calcium and magnesium on PDE-1 activity of crude extract during solubilisation at 4 0 C. 10 We sought to determine whether calcium and magnesium would have an effect on stabilisation of PDE-1 in the crude extract, or otherwise, on preserving or enhancing PDE-1 activity of the crude extract, during the step of solubilising PDE-1 at 4'C that follows the homogenisation step described in Example 6. To this end we maintained the homogenised extract at 4'C in 25mM Tris HC1 15 (pH8.9): (i) in the absence of calcium and magnesium; (ii) with 5mM MgCl 2 and 5mM CaC1 2 ; and (iii) with 50mM MgCl 2 and 50mM CaC1 2 . We found that calcium and magnesium enhanced and indeed stabilised PDE-1. At 50mM MgCl 2 and 50mM CaCl 2 , the PDE-1 activity was 22% greater than in the sample with no magnesium or calcium (92 x 103 pmoles/min/mL compared to 75 x 10 3 20 pmoles/min/mL).
WO 2004/101613 PCT/AU2003/001618 11 Example 10. Effect of calcium and magnesium on PDE-1 activity of crude extract during heat treatment. We sought to determine whether calcium and magnesium would have an effect on stabilisation of PDE- 1 in the crude extract or otherwise on preserving or enhancing PDE 5 1 activity of the crdue extract, during the step of heating PDE- 1 as described in Example 7. To this end, we incubated the crude extract at 60'C for 1 hour in 25mM Tris HCl (pH8.9): (i) in the absence of calcium and magnesium; (ii) with 5mM MgCl 2 and 5mI4 CaCl 2 ; and (iii) with 50mM MgCl 2 and 50mM CaCl 2 . 10 We found that after heating, the activity dropped significantly in samples without magnesium and calcium and in samples with 5mM MgCl 2 and 5mM CaCl 2 by over 40% compared with samples with 50mM MgCl 2 and 50mM CaCl 2 (46 x10 3 pmoles/min/mL and 48 x10 3 ptmoles/min/mL compared with 78 x10 3 tmoles/min/mL).
Claims (18)
1. A process for purifying a phosphodiesterase 1 (PDE-1) from a cell including heating an extract of a cell formed from a solution including divalent cations magnesium and calcium to increase the specific activity of PDE- 1 in the extract. 5
2. A process according to claim I wherein the concentration of the divalent cations is less than 100mM.
3. A process according to claim 2 wherein the concentration of the divalent cations is about 10 to 50 mM.
4. A process according to claim 3 wherein the concentration of the divalent cations is about 50 10 mM.
5. A process according to any one of claims 1-4 wherein the extract is heated to a temperature that permits depletion of phosphomonoesterase activity from the extract.
6. A process according to claim 5 wherein the extract is heated to less than 80'C.
7. A process according to claim 6 wherein the extract is heated to between about 45 and 75*C. 15
8. A process according to claim 7 wherein the extract is heated to about 60*C.
9. A process for purifying PDE-1 from a barley cell including: releasing PDE-1 from the cell into a solution including calcium and magnesium to form an extract; and heating the extract to increase the specific activity of PDE- 1 in the extract.
10. A process according to claim 9 wherein the extract is maintained in conditions for promoting 20 solubilisation of the phosphodiesterase in the extract prior to heating the extract.
11. A process according to claim 10 wherein the extract is maintained at less than 10*C.
12. A process according to claim 11 wherein the extract is maintained at between 0 to about 4C. 13
13. A process according to any one of claims 9-12 comprising the further step of utilising chromatography to purify PDE-1 from the heated extract.
14. A process according to claim 13 wherein anion exchange chromatography is utilised to purify PDE-1 from the heated extract. 5
15. A PDE-1 purified by a process according to any one of the preceding claims.
16. A cell including PDE-1 wherein the PDE-1 is produced by a process according to any one of claims 1-14.
17. A process for producing a ribonucleotide including contacting a polyribonucleotide with a PDE- 1 according to claim 15 to produce the ribonucleotide. 10
18. A ribonucleotide produced by a process according to claim 17.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2003304117A AU2003304117B2 (en) | 2003-05-14 | 2003-12-04 | Extracting and purifying enzymes |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2003902303A AU2003902303A0 (en) | 2003-05-14 | 2003-05-14 | Extracting and purifying enzymes |
| AU2003902303 | 2003-05-14 | ||
| PCT/AU2003/001618 WO2004101613A1 (en) | 2003-05-14 | 2003-12-04 | Extracting and purifying enzymes |
| AU2003304117A AU2003304117B2 (en) | 2003-05-14 | 2003-12-04 | Extracting and purifying enzymes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2003304117A1 AU2003304117A1 (en) | 2004-12-03 |
| AU2003304117B2 true AU2003304117B2 (en) | 2010-09-23 |
Family
ID=34394722
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2003304117A Ceased AU2003304117B2 (en) | 2003-05-14 | 2003-12-04 | Extracting and purifying enzymes |
Country Status (1)
| Country | Link |
|---|---|
| AU (1) | AU2003304117B2 (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3516907A (en) * | 1961-02-04 | 1970-06-23 | Waldhof Zellstoff Fab | Method for producing 5'-mononucleotides |
-
2003
- 2003-12-04 AU AU2003304117A patent/AU2003304117B2/en not_active Ceased
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3516907A (en) * | 1961-02-04 | 1970-06-23 | Waldhof Zellstoff Fab | Method for producing 5'-mononucleotides |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003304117A1 (en) | 2004-12-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7065970B2 (en) | A novel process for the production of oligonucleotides | |
| Irie | Isolation and properties of a ribonuclease from Aspergillus saitoi | |
| US7893249B2 (en) | Deprotection and purification of oligonucleotides and their derivatives | |
| JP3662020B2 (en) | Method for purifying collagenase | |
| US20040137596A1 (en) | Method for purifying an enzyme, a purified enzyme produced thereby, and use of this enzyme | |
| Zytko et al. | Ribonucleases of rat liver: I. Partial purification and properties | |
| Cuchillo et al. | Pancreatic ribonucleases | |
| EP1631583B1 (en) | Extracting and purifying enzymes | |
| AU2003304117B2 (en) | Extracting and purifying enzymes | |
| Bigelis et al. | Purification of yeast alpha-isopropylmalate isomerase. High ionic strength hydrophobic chromatography | |
| CN112080485A (en) | Method for extracting ribonuclease from bovine pancreas | |
| McKeon et al. | Purification and characterization of two ribonucleases from developing tomato fruit | |
| Wang et al. | Joining of yeast alanine transfer ribonucleic acid half molecules to form a whole molecule by T4 RNA ligase | |
| Mulcahy et al. | Effect of accessible immobilized NAD+ concentration on the bioaffinity chromatographic behavior of NAD+-dependent dehydrogenases using the kinetic locking-on strategy | |
| Padmanabhan et al. | Enhanced leaching of product at elevated temperatures: alpha‐amylase produced by Bacillus licheniformis M27 in solid state fermentation system | |
| AU2006284545B2 (en) | Extracting and purifying limit dextrinases | |
| TERAO et al. | Purification and properties of phosphodiesterase from bovine pancreas | |
| Shetty et al. | A rapid method for the isolation of ribonuclease from yeast (Saccharomyces carlsbergensis) | |
| US20090123987A1 (en) | Extracting and purifying limit dextrinases | |
| US20090137022A1 (en) | Extracting and purifying beta 1,4-xylanase | |
| WO2007134365A1 (en) | EXTRACTING AND PURIFYING β-AMYLASES | |
| Nogués | Pancreatic ribonucleases | |
| WO2007134366A1 (en) | Extracting and purifying α-amylase | |
| Lee et al. | The separation of two deoxyribonucleases from extracts of intestinal mucosa of the rat | |
| CS263588B1 (en) | Process for preparing d-galactopyranuroic acid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |